BTK Inhibitor Ibrutinib/Zanubrutinib Plus Bendamustine and Rituximab As the Initial Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia : a Single Arm Real-World Study

被引：0
|
作者：
Zhu, Huayuan [1 ,2 ]
Wu, Wei [1 ,2 ]
Sha, Yeqin [1 ,2 ]
Jin, Ze [1 ,2 ]
Yang, Yilian [2 ]
Qiu, Jingyan [2 ]
Ding, Chongyang [3 ]
Wang, Zhen [4 ]
Shi, Chuanbing [5 ]
Peng, Chen [2 ]
Mi, Hongling [2 ]
Chen, Ruize [1 ,2 ]
Wang, Li [1 ,2 ]
Fan, Lei [1 ,2 ]
Xu, Wei [1 ,2 ]
Li, Jianyong [1 ,2 ]
机构：
[1] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Hematol, Nanjing, Peoples R China
[2] Jiangsu Prov Hosp, Pukou Div, Pukou CLL Ctr, Nanjing, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Nucl Med, Nanjing, Peoples R China
[4] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Pathol, Nanjing, Peoples R China
[5] Jiangsu Prov Hosp, Pukou Div, Dept Pathol, Nanjing, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152147
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4697
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Real-World Study of Zanubrutinib Treatment in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Zhu, Huayuan
    Xia, Yi
    Miao, Yi
    Qin, Shuchao
    Wu, Wei
    Qiu, Tonglu
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    [J]. BLOOD, 2023, 142
  • [2] Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As the Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia: A Single-Center Real World Study
    Zhu, Huayuan
    Shen, Hui
    Yang, Yilian
    Ding, Chong-Yang
    Sha, Yeqin
    Mi, Hongling
    Qiu, Jingyan
    Chen, Ruize
    Wu, Yujie
    Qiao, Chun
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    [J]. BLOOD, 2020, 136
  • [3] Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL)
    Krackeler, Margaret
    Chee, Bryant
    Orchanian, Arthur K.
    Law, Lisa Y.
    Lopez, Alfredo R.
    Buchanan, Susan
    Maglinte, Gregory A.
    Liu, Raymond
    Zhu, Zheng
    Sakoda, Lori C.
    Tavakoli, Jahan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia
    Geethakumari, Praveen Ramakrishnan
    Awan, Farrukh
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (10) : 1039 - 1046
  • [5] Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia
    Zhu, Huayuan
    Sha, Yeqin
    Miao, Yi
    Qin, Shuchao
    Shen, Hui
    Qiu, Jingyan
    Wu, Wei
    Xia, Yi
    Qiu, Tonglu
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    [J]. BLOOD, 2022, 140 : 4164 - 4165
  • [6] Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
    Wei Xu
    Shenmiao Yang
    Keshu Zhou
    Ling Pan
    Zengjun Li
    Jianfeng Zhou
    Sujun Gao
    Daobin Zhou
    Jianda Hu
    Ru Feng
    Haiwen Huang
    Meng Ji
    Haiyi Guo
    Jane Huang
    William Novotny
    Shibao Feng
    Jianyong Li
    [J]. Journal of Hematology & Oncology, 13
  • [7] Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
    Xu, Wei
    Yang, Shenmiao
    Zhou, Keshu
    Pan, Ling
    Li, Zengjun
    Zhou, Jianfeng
    Gao, Sujun
    Zhou, Daobin
    Hu, Jianda
    Feng, Ru
    Huang, Haiwen
    Ji, Meng
    Guo, Haiyi
    Huang, Jane
    Novotny, William
    Feng, Shibao
    Li, Jianyong
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [8] Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
    Zhu, Huayuan
    Miao, Yi
    Sha, Yeqin
    Xia, Yi
    Qin, Shuchao
    Jiang, Rui
    Dai, Luomengjia
    Shen, Hui
    Qiu, Tonglu
    Wu, Wei
    Ding, Chongyang
    Wu, Yujie
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 : S93 - S94
  • [9] Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
    Yi Miao
    Yeqin Sha
    Yi Xia
    Shuchao Qin
    Rui Jiang
    Luomengjia Dai
    Hui Shen
    Tonglu Qiu
    Wei Wu
    Jingyan Qiu
    Yilian Yang
    Chongyang Ding
    Yujie Wu
    Lei Fan
    Wei Xu
    Jianyong Li
    Huayuan Zhu
    [J]. Blood Cancer Journal, 13
  • [10] Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
    Miao, Yi
    Sha, Yeqin
    Xia, Yi
    Qin, Shuchao
    Jiang, Rui
    Dai, Luomengjia
    Shen, Hui
    Qiu, Tonglu
    Wu, Wei
    Qiu, Jingyan
    Yang, Yilian
    Ding, Chongyang
    Wu, Yujie
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    Zhu, Huayuan
    [J]. BLOOD CANCER JOURNAL, 2023, 13 (01)
12345